Pentagon’s Rapid Ozempic Purchases: What It Means for Government Contractors

The Department of Defense (DoD) is making headlines for a surprising reason: a dramatic surge in spending on GLP-1 weight loss drugs like Ozempic. While these medications are often associated with civilian healthcare trends, the Pentagon has rapidly increased its investment in them—signaling new priorities, policy shifts, and emerging opportunities for government contractors.

In this article, we’ll break down what’s happening, why it matters, and how businesses can position themselves to benefit from this growing federal market trend.

Pentagon Spending on GLP-1 Drugs: The Shocking Growth Numbers

Government contracting often moves slowly—but not this time. The Pentagon’s spending on GLP-1 weight loss drugs grew 232% from FY2022 to FY2023 and is projected to jump another 306% in FY2024.

To put this into perspective:

• $123 million was spent on these drugs in FY2023 alone.

• That might seem modest for the pharmaceutical industry, but for federal procurement, this kind of growth is massive and rare.

This trend suggests that the government is prioritizing health initiatives aimed at reducing obesity and improving readiness among service members—issues that directly impact operational capability and long-term healthcare costs.

Why Is the Pentagon Buying Ozempic?

The Department of Defense’s interest in GLP-1 drugs like Ozempic isn’t about following a fad—it’s about combat readiness and long-term healthcare savings. Military obesity rates have been climbing, creating both health risks and readiness challenges. GLP-1 medications are increasingly recognized for their ability to support weight loss and reduce cardiovascular risks.

The surge in purchases aligns with broader policy changes:

• The Department of Veterans Affairs (VA) is emphasizing cardiovascular health initiatives.

• Medicare Part D has expanded coverage for these drugs.

• Tricare—the military healthcare system—recently began covering certain GLP-1 medications for active-duty members, retirees, and families.

These shifts indicate that GLP-1 drugs are no longer considered niche treatments. They are becoming central to government health policy, driving sustained demand.

Sole-Source Contracts Dominate This Market

One of the most important factors contractors need to understand: nearly all of these purchases are sole-source contracts. Why? Because the pharmaceutical companies producing GLP-1 drugs hold the patents, creating a monopoly in the space.

This means:

• If you’re not the patent holder, you can’t compete directly for these contracts.

• However, subcontracting and partnerships present big opportunities for smaller businesses.

Prime contractors holding these contracts often need logistics support, distribution partners, or companies that provide complementary services. If you’re in healthcare logistics, IT support for medical procurement, or compliance consulting, there’s room for you to enter the ecosystem.

Where Are These Contracts Managed?

Most procurement for GLP-1 drugs flows through the Defense Logistics Agency’s (DLA) troop support medical supply chain located in Philadelphia, Pennsylvania.

Unlike in commercial markets, government contracting provides full transparency about where buying decisions happen and who makes them. This allows businesses to target the right offices and build relationships with key decision-makers—a crucial advantage for anyone looking to break into this market.

Policy Shifts Are Driving Demand

The DoD’s move to purchase these drugs isn’t happening in isolation. It’s part of a larger policy-driven trend:

• The VA’s focus on cardiovascular risk reduction.

• Tricare’s inclusion of GLP-1 drugs in its coverage.

• Medicare’s expansion under Part D.

For contractors, these policy shifts are more than background noise—they’re early indicators of demand growth. When healthcare programs adopt a new standard of care, procurement typically scales quickly across multiple agencies.

Opportunities for Contractors: Where Do You Fit In?

If you’re not a pharmaceutical giant, you may think this trend doesn’t apply to you. But the truth is, government spending creates ripple effects across multiple industries. Here are a few entry points:

• Subcontracting with Prime Vendors: The sole-source nature of GLP-1 drug contracts limits direct access, but primes often need support with logistics, compliance, IT, and distribution.

• Complementary Services: Think about data analytics, health IT, telehealth platforms, or patient support services. These will become increasingly critical as agencies scale up usage.

• Policy & Compliance Consulting: Agencies and contractors alike need guidance on staying compliant as procurement accelerates.

• Marketing & Outreach for Primes: Pharmaceutical companies are large, but their federal market teams often rely on specialized firms for proposal support, BD strategy, and compliance assistance.

Transparency = Advantage

One of the unique aspects of government contracting is data availability. Tools like SAM.gov and USA Spending allow you to see:

• Which agencies are buying.

• Which vendors hold prime contracts.

• How much is being spent.

By leveraging this data, businesses can strategically target opportunities instead of guessing where the demand is.

The Bigger Picture

At first glance, the Pentagon’s interest in weight loss drugs may seem like a niche procurement story—but it’s actually a blueprint for how emerging trends create new contracting opportunities.

Here’s what this case teaches us:

• Policy shifts signal demand before the dollars hit—follow the policy, and you’ll see where the money goes.

• Even sole-source markets offer opportunity through subcontracting and support services.

• Transparency gives you a competitive edge—if you know how to use the data.

The DoD’s growing investment in GLP-1 drugs reflects a fundamental shift in military health strategy. For savvy contractors, it’s a chance to position early and ride the wave as demand scales.

Final Thoughts

Government contracting success isn’t about chasing random opportunities—it’s about spotting patterns and aligning early. The Pentagon’s surge in GLP-1 drug purchases is a perfect example of how small market signals turn into big federal spending trends.

If you’re serious about breaking into or scaling in government contracting, start paying attention to policy, leverage data tools, and build relationships where the action is happening.

👉 Want to start your own government contracting consulting business, land a high-paying GovCon sales role, or scale your company’s federal sales pipeline?
Visit GovClose.com and join thousands of professionals mastering federal sales.

Follow Richard C. Howard on LinkedIn for free insights and live training on winning in the government marketplace.

Subscribe now

---

Ready to go pro?

The GovClose Professional Training Program is built for people ready to commit to learning a new skill set, implementing that skill set, and working with a community of professionals who are serious about winning in the federal market.

If you think you have what it takes, set up an enrollment interview with the GovClose advisory team.